Cordyceps militaris and mycelial fermentation induced apoptosis and autophagy of human glioblastoma cells

C-H Yang1,5, Y-H Kao2,5, K-S Huang3, C-Y Wang4 and L-W Lin3

This study is the first report that investigated the apoptosis-inducing effects of Cordyceps militaris (CM) and its mycelial fermentation in human glioblastoma cells. Both fractions arrested the GBM8401 cells in the G0/G1 phase, whereas the U-87MG cells were arrested at the G2/M transitional stage. Western blot data suggested that upregulation of p53 and p21 might be involved in the disruption of cell cycle progression. Induction of chromosomal condensation and the appearance of a sub-G1 hypodiploid population further supported the proapoptogenicity, possibly through the activation of caspase-3 and caspase-8, and the downregulation of antiapoptotic Bcl-2 and the upregulation of proapoptotic Bax protein expression. Downregulation of mammalian target of rapamycin and upregulation of Atg5 and LC3 II levels in GBM8401 cells implicated the involvement of autophagy. The signaling profiles with mycelial fermentation treatment indicated that mycelial fermentation triggered rapid phosphorylation of Akt, p38 MAPK, and JNK, but suppressed constitutively high levels of ERK1/2 in GBM8401 cells. Mycelial fermentation treatment only significantly increased p38 MAPK phosphorylation, but decreased constitutively high levels of Akt, ERK1/2, and JNK phosphorylation in U-87MG cells. Pretreatment with PI3K inhibitor wortmannin and MEK1 inhibitor PD98059 prevented the mycelial fermentation-induced cytotoxicity in GBM8401 and U-87MG cells, suggesting the involvement of PI3K/Akt and MEK1 pathways in mycelial fermentation-driven glioblastoma cell apoptosis and autophagy.

Received 16.5.12; revised 08.10.12; accepted 09.10.12; Edited by A Stephanou

Keywords: Cordyceps militaris; mycelial fermentation; anticancer; apoptosis; signaling pathway

Abbreviations: MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide; CM, Cordyceps militaris; IC50, half-maximal inhibitory concentration

Subject Category: Cancer

Cordyceps spp., including Cordyceps militaris (CM) and C. sinensis, are a type of Ascomycete, it parasites insect larvae, grows, and gradually turns into a mature fruiting body. The parasitic complex of fungus and caterpillar has been used for tonics and medicinal purposes for centuries in eastern Asia.1,2 It is commonly used to treat fatigue, renal and pulmonary dysfunction, hyperglycemia, hyperlipidemia, and heart disease, such as arrhythmia. C. sinensis (known as caterpillar fungus) has long been demonstrated to possess many bioactive ingredients, such as 3’-deoxyadenosine (cordycepin), cordycepic acid, and Cordyceps polysaccharides.3-5 Although the pharmacologically active components are still not fully resolved, at least two chemical constituents, cordycepin and cordycepic acid, have been identified and proposed as important bioactive constituents. Decades ago, because of the rarity of wild C. sinensis, scientists began to study the artificial cultivation of natural Cordyceps and how to produce them using fermentation technology.6 Compared with C. sinensis, mycelia of CM are easier to grow under an artificial environment, and the process of producing CM fruiting bodies is similar to that of other cultivated edible mushrooms.7 Previous biochemical analyses revealed that CM has a similar composition and pharmacological activity to C. sinensis in terms of production of cordycepin,6 and polysaccharides.9 Both C. sinensis and CM are sources of biochemicals with interesting biological and pharmacological properties, showing significant anticancer activities.10

Recently, mycelial extracts, purified nature product, submerged culture, and water extract of Cordyceps have shown a number of far-reaching medicinal effects.11 For example, mycelial extracts of Cordyceps have been found to possess diverse biological activities, including anti-inflammation, anti-oxidation bioactivities, and an immunostimulatory effect.12-14 Nature product of Cordyceps has shown that cordycepin, one of the main constituents of CM, exhibits an antitumor effect in some tumor cell lines.15 Polysaccharides–peptide complexes isolated from submerged culture of C. sphenocerephala mycelia induce apoptosis of human hepatocarcinoma HepG2 and neuroblastoma SKN-SH cells.16 In addition, water extract of CM may inhibit tumor cell proliferation via arresting the cell cycle at the G2/M phase and induce apoptosis through upregulation of p53, p21, and cyclin B1, as well as the activation of caspase-8, caspase-9, and caspase-3.17,18 In addition, animal studies have shown that CM extract effectively suppresses the growth of various tumor cell explants and angiogenesis.19 Cordyceps has only become known to most people within the past 100 years.20 During that time, modern scientific
methods have been increasingly applied to investigate its possible large range of medicinal applications.\textsuperscript{21,22} Although the proapoptotic effect of CM has been tested in several tumor cells, there are scant reports on its efficacy in the treatment of glioblastoma, a group of heterogeneous and highly malignant primary brain tumors with survival rates that rarely exceed 12 to 15 months after diagnosis.\textsuperscript{23,24} Thus, this study aimed to investigate whether CM and its mycelial fermentation equally induce apoptosis of glioblastoma cells \textit{in vitro}, and to elucidate the pathways involved in the CM-driven proapoptogenic signaling.

**Results**

**Growth inhibition in cancer cell lines.** To test the cytostatic effect of CM and mycelial fermentation on the proliferation of 3T3, MCF-7, GBM8401, and U-87MG cells, the cells were treated with different concentrations of CM or mycelial fermentation. After 24 h incubation, the cell viability and viable cell number were measured using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay and Trypan blue exclusion method, respectively. The results show that treatment with CM or mycelial fermentation significantly reduced viability of four cell lines in a dose-dependent manner (Figure 1). This cytotoxic effect of both fractions in GBM8401 and U-87MG glioblastoma cells appeared higher than that observed in 3T3 and MCF-7 cells. The calculated half-maximal inhibitory concentration ($IC_{50}$) of CM was 1.0 and 1.2 mg/ml for GBM8401 and U-87MG cells, respectively. The $IC_{50}$ of mycelial fermentation treatment was 1.6 and 2.3 mg/ml for GBM8401 and U-87MG cells, respectively.

**Influence of morphological change.** To observe whether CM and/or mycelial fermentation induces the apoptosis-related morphological alterations in GBM8401 and U-87MG glioblastoma cells, the cells treated were stained with 4,6-diamidino-2-phenylindole (DAPI) and examined under fluorescent microscope. The control cells displayed an intact and homogeneous nuclear structure. Both GBM8401 and U-87MG cells showed cell shrinkage after CM or mycelial biomass treatment, as well as cytoplasm condensation and the appearance of apoptotic bodies. In particular, the formation of chromosomal condensation was noted in both DAPI-stained cells with both CM and mycelial fermentation treatments (Supplementary Figure S1).

**Induction of sub-G1 population and disturbance of cell cycle progression.** To investigate the possible apoptosis in this context, glioblastoma cells were treated with 1 mg/ml CM or 2 mg/ml mycelial fermentation for 24 h and received PI staining and subsequent flow cytometric detection. The

![Figure 1](image-url)  
**Figure 1** Effects of CM and mycelial fermentation (MF) on the viability of 3T3 fibroblasts and cancer cells. 3T3 fibroblasts (a), MCF-7 breast cancer cells (b), GBM8401 (c), and U-87MG (d) glioblastoma cells were treated with either CM or MF at a concentration of 0.5, 1, 1.5, 2, and 2.5 mg/ml and incubated for 24 h. The cell viability was monitored by using MTT assay. Data are means ± S.D. of five independent experiments ($P < 0.05$)
Histogram analysis for sub-G1 population revealed that both CM and mycelial fermentation significantly increased chromosomal hypodipoidy in GBM8401 (Figure 2a) and U-87MG cells (Figure 2b). On the other hand, a kinetic analysis on early apoptotic events indicated that the mycelial fermentation of CM induced Annexin V presentation in a time-dependent manner (Figure 2c). These results suggest that the cytotoxic effects might be associated with the induction of apoptotic cell death in glioblastoma cells, and that GBM8401 cells were more sensitive to CM treatment than U-87MG cells. Moreover, the cells beyond the sub-G1 region were further used for analysis of cell cycle distribution. The data indicated that treatment with CM or mycelial fermentation for 24 h significantly increased the percentage of GBM8401 cells in the G0/G1 phase, with a concurrent decrease in the G2/M phase. However, the same treatment induced the G2/M-phase arrest and decreased the G0/G1 cell population in U-87MG cells (Table 1). These results

![Figure 2](image)

**Figure 2** Induction of hypodiploidic DNA contents and Annexin V positivity in human glioblastoma cells. Cultured human glioblastoma cells, GBM8401 (a) and U-87MG (b), were treated with either CM or mycelial fermentation (MF) for 24 h at the dose indicated, followed by propidium iodide (PI) staining and subsequent flow cytometric detection. The representative sub-G1 histogram profiles from three independent experiments are shown. (c) GBM8401 cells were treated with MF for indicated duration and subjected to Annexin V-FITC and PI detection by using flow cytometry. The percentage of sub-G1 and Annexin V-positive fractions in total cell populations is measured as mean ± S.D. NC, negative control

**Table 1** The modulatory effect of CM and mycelial fermentation on the cell cycle distribution of a non-apoptotic fraction of human glioblastoma GBM8401 cells and human glioblastoma U-87MG cells

| Dose       | GBM8401 cell cycle distribution | U-87MG cell cycle distribution |
|------------|---------------------------------|-------------------------------|
|            | % G0/G1 | % S | % G2/M | % G0/G1 | % S | % G2/M |
| C. militaris |        |    |        |         |    |        |
| 0          | 63.5 ± 2.7 | 19.8 ± 2.2 | 17.5 ± 2.4 | 69.4 ± 2.8 | 12.4 ± 2.4 | 18.4 ± 2.6 |
| 1          | 70.5 ± 3.5* | 24.7 ± 2.3 | 5.2 ± 2.7* | 59.5 ± 2.6* | 14.6 ± 2.4 | 26.2 ± 3.3* |
| 2          | 82.3 ± 5.8* | 16.1 ± 2.3 | 1.8 ± 2.2* | 45.7 ± 3.5* | 9.8 ± 3.6 | 45.3 ± 4.3* |
| Mycelial fermentation |        |    |        |         |    |        |
| 0          | 58.2 ± 2.4 | 18.9 ± 2.2 | 16.2 ± 2.4 | 72.6 ± 2.7 | 11.7 ± 2.3 | 15.7 ± 2.5 |
| 1          | 61.9 ± 2.3 | 17.0 ± 2.3 | 16.8 ± 2.6 | 69 ± 2.4 | 15 ± 3.1 | 24 ± 2.7* |
| 2          | 70.8 ± 6.7* | 21.3 ± 3.3 | 8.5 ± 2.3* | 45.8 ± 2.5* | 9.8 ± 2.9 | 45.4 ± 3.7* |

Note: GBM8401 and U-87MG cells were treated with either CM or mycelial fermentation at the indicated dose for 24 h, followed by PI staining and subsequent flow cytometry. Data are shown as means ± S.D. from three independent measurements. *P<0.05 using Student’s t-test compared with respective negative control.
Caspase activation. To determine which caspase pathway is activated in glioblastoma cells by CM and mycelial fermentation treatment, the cell lysates were collected and incubated with luminogenic-specific substrates for caspase-3, caspase-8, or caspase-9. The results shown in arbitrary activity unit demonstrated that both CM and mycelial fermentation significantly elicited caspase-3 and caspase-8 activation, but not caspase-9 activity in GBM8401 (Figure 3a) and U-87MG glioblastoma cells (Figure 3b). Furthermore, pretreatment with caspase-specific inhibitor confirmed the contribution of caspase-3 and -8 activities to cell death induction (Figure 3c). These results suggest that only the extrinsic apoptotic pathway is involved in CM-mediated glioblastoma cytotoxicity.

Regulatory disruption of cell cycle, apoptosis, and autophagy. To elucidate the molecular mechanisms underlying the cell cycle arrest and apoptotic induction by mycelial fermentation of CM, the total protein extracts from GBM8401 and U-87MG cells were subjected to western blotting. The results indicate that the upregulation of p53 and p21 proteins known for cell cycle regulation were seen dose-dependently in the GBM8401, but not the U-87MG cells exposed to CM mycelial fermentation (Figure 4a; scanned density data are referred to Supplementary Figure S2). On the other hand, the mycelial fermentation prominently downregulated Bcl-2 abundance, but upregulated Bax protein levels, which collectively might account for the apoptotic induction in both glioblastoma cells (Figure 4b). In the context of autophagic induction, a downregulation of mammalian target of rapamycin (mTOR) and upregulation of Atg5 and microtubule-associated protein light chain II (LC3 II) were seen in GBM8401 cells (Figure 4c), suggesting the involvement of autophagy in the cell death.

Signaling profiles and the kinase activity involved in glioblastoma cell apoptosis. Western blotting data clearly demonstrated that Akt and JNK1 phosphorylation levels in U-87MG cells is constitutively higher than those in GBM8401 cells, whereas ERK1/2 was highly phosphorylated in both cell lines. It is worth noting that treatment with CM mycelial fermentation instantly triggered Akt, p38 MAPK, and within 10 min JNK1 phosphorylation in GBM8401 cells, while the upregulated phosphorylation all diminished within 2 h (Figure 5a; scanned density data are referred to Supplementary Figure S3). On the other hand, only p38 MAPK phosphorylation in U-87MG cells was enhanced by mycelial fermentation treatment, and the enhancement peaked 1 h after treatment. Besides, the constitutive phosphorylation of JNK1 ceased dramatically, while that of Akt was not affected (Figure 5b). Coincidently, the constitutive ERK1/2 phosphorylation in both cells was significantly suppressed by the treatment.

To determine the signaling pathways involved in the CM-induced cytotoxicity, glioblastoma cells were pretreated indicate that CM and mycelial fermentation differentially arrest the cell cycle progression of GBM8401 and U-87MG glioblastoma cells in the G0/G1 and G2/M phases, respectively.

**Figure 3** Caspase activation in human glioblastoma cells. Cultured human glioblastoma GBM8401 (a) and U-87MG (b) cells were treated with CM or mycelial fermentation (MF) for 6 h at 2 mg/ml, followed by lysis and subsequent luminometrical detection for activities of caspase-3, caspase-8, and caspase-9. Caspase activity readings were normalized by total protein. The representative data in arbitrary luminescent unit are shown as mean ± S.D. from three independent experiments. *P < 0.05, as compared with control group. (c) Both glioblastoma cells were pretreated either with Asp-Met-Gln-Asp-fluoromethyl ketone (Z-DEVD-FMK), Leu-Glu-His-Asp-fluoromethyl ketone (Z-IETD-FMK), or Ile-Glu-Thr-Asp-fluoromethyl ketone (Z-LEHD-FMK) peptides at 20 μM for 1 h to block caspase-3, caspase-8, and caspase-9 activity, respectively, or with equivalent dimethylsulfoxide (DMSO) for solvent control. The cell viability after 24 h of MF treatment was determined by MTT assay. The representative data are shown as mean ± S.D. from three independent experiments. *P < 0.05, as compared with DMSO solvent control group. NC, negative control.
with different kinase inhibitors followed by mycelial fermentation treatment, and then the effect of kinase blockade was monitored by MTT cell viability assay. The results show that kinase inhibitor alone did not affect basal viability of glioblastoma cells, except that blockade of JNK activity remarkably suppressed U-87MG cell proliferation. Moreover, only treatment with PI3K inhibitor wortmannin significantly reversed the mycelial fermentation-induced GBM8401 cytotoxicity (Figure 6a). By contrast, the CM-induced cytotoxicity in U-87MG cells was prevented by MEK1 inhibitor PD98059, but significantly potentiated by pretreatment with JNK inhibitor SP600125 and wortmannin (Figure 6b).

**Discussion**

The *in vitro* proapoptotic effect of fermentation of CM has been addressed in solid tumors and hematopoietic cancer. In that regard, the activation of effector caspases and upstream initiator caspases has been previously evidenced in many kinds of tumor cells treated with either fermentation or specified constituents from different *Cordyceps* species, including *C. spheocephala*, *C. pruina*, *C. sinensis*, as well as CM. This study demonstrated that both preparations induced glioblastoma cell apoptosis through caspase- and Bcl-2/Bax-mediated pathways (Figures 3 and 4). In agreement with our finding, the downregulation of antiapoptotic Bcl-2 expression has been noted in *Cordyceps* extract-treated A549 lung carcinoma cells, HeLa cells, HepG2 hepatoblastoma cells, and leukemia cells. Similar to our results, the fermentation of CM has been found to induce Bcl-2 downregulation, but not affect Bax protein levels and caspase-9 activity in apoptotic U937 leukemia cells. It is worth noting that the treatment with CM fermentations led to the activation of caspase-8 but

---

**Figure 4** Modulatory effects of mycelial fermentation (MF) of CM on regulator expression of cell cycle, apoptosis, and autophagy in human glioblastoma cells. GBM8401 and U-87MG cells were treated with MF at the indicated doses for 24 h, and the lysates were subjected to western blotting detection. (a) MF induced a significant upregulation of p53 and its downstream p21 expression in GBM8401, but not U-87MG cells. (b) MF treatment diminished the expression of antiapoptotic Bcl-2 protein, and conversely increased the abundance of proapoptotic Bax protein in both glioblastoma cells. (c) MF reduced mTOR expression but increased Atg5 and LC3 II levels in GBM8401 cells. Although MF upregulated mTOR content, MF did not affect the levels of autophagic regulators in U-87MG cells. The representative result of three independent experiments is shown.

---

**Figure 5** Effects of mycelial fermentation (MF) of CM on signaling profiles in human glioblastoma cells. GBM8401 (a) and U-87MG (b) cells were treated with 1 mg/ml of MF of CM for the indicated duration, and the lysates were subjected to western blotting detection. The representative result of three independent experiments is shown.
mutated in GBM8401 cells, whereas U-87MG cells possess been well documented that the tumor suppressor gene p53 is dominant mediated through an extrinsic apoptotic pathway. 

Collectively support that the CM-induced apoptosis is pre-

Figure 6 Involvement of kinase activity in the CM-induced cytotoxicity in human glioblastoma cells. GBM8401 (a) and U-87MG (b) cells cultivated in a 96-well plate were pretreated with either 0.1% dimethylsulfoxide (DMSO) as solvent control or with 10 μM of selective kinase inhibitors, including SB203580 (SB), SP600125 (SP), PD98059 (PD), and wortmannin (WM), at 2 h before treatment with or without 2 mg/ml of mycelial fermentation (MF) of CM. After 24 h of treatment, the CM-driven cytotoxicity was evaluated by MTT assay. Data are presented as mean ± S.D. from three independent experiments. *P < 0.05, as compared between groups; &P < 0.05, as compared with negative control (NC) groups using Student’s t-test.

Not of caspase-9, resulting in the subsequent activation of effector caspase-3 (Figure 3). Moreover, the phosphorylated form of JNK, a regulator of caspase-9-mediated apoptosis, was not remarkably increased by the treatment (Figure 5). Because the death receptor-activated and caspase-8-initiated extrinsic apoptotic pathway is recently being considered a preferential target for cancer therapy,29 our observations collectively support that the CM-induced apoptosis is predominantly mediated through an extrinsic apoptotic pathway.

However, two different patterns of cell cycle retardation (i.e. G0/G1 and G2/M phase growth arrests) were seen in GBM8401 and U-87MG cells, respectively (Table 1). It has been well documented that the tumor suppressor gene p53 is mutated in GBM8401 cells, whereas U-87MG cells possess wild-type p53 but mutant PTEN genes.30 The discrepancy in genetic background of these two glioblastoma cell lines may constitute the differential response of the cell cycle regulatory machinery. In fact, PTEN is well known to regulate negatively the PI3K/Akt pathway, one of the most important pathways for cell growth, proliferation, and survival.31 On the one hand, Akt phosphorylates and activates MDM2, a p53-binding protein that targets p53 for its proteasomal degradation. On the other hand, Akt also phosphorylates and inactivates glycogen synthase kinase-3, resulting in the stabilization of cyclin D1 and the downregulation of p27, a negative regulator of cyclin-dependent kinases. Conversely, PTEN coordinates the G1 arrest of breast cancer cells by downregulating cyclin D1 via its protein phosphatase activity and upregulating p27 via its lipid phosphatase activity.32 Loss of PTEN function results in Akt hyperactivation due to increased concentrations of phosphatidylinositol 3,4,5-triphosphate (PIP3), as reflected by the higher constitutive level of Akt phosphorylation in U-87MG cells than that in GBM8401 cells (Figure 5b). Moreover, cordycepin causes p21WAF1-mediated G2/M cell cycle arrest of human bladder cancer T-24 cells bearing the mutant PTEN gene,15 while PTEN gene delivery into T-24 cells induced G1 growth arrest.33 Therefore, PTEN deficiency is believed to contribute to genomic instability and alteration in multiple cell cycle checkpoints.34 This coincides with the finding of CM-induced G1 growth arrest in GBM8401 cells (Table 1).

In the context of the regulatory roles of MAPK signaling mediators in the mechanism of Cordyceps-induced apoptosis, a comparison among the signaling profiles elicited by various constituents of CM or relative species under different scenarios may provide insightful implications. Although methanol extract of CM has recently been reported to induce IL-8 expression in human lung carcinoma A549 cells via ERK and JNK signaling pathways,35 water extract was also found to induce A549 cell apoptosis through both death receptor-mediated extrinsic and mitochondria-mediated intrinsic pathways.19 The significance of ERK in glioblastoma carcinogenesis may be reflected by the constitutive activation of ERK1/2 in both cell lines (Figure 5), while the attenuation of CM fermentation-induced cytotoxicity in U-87MG cells by inhibition of ERK cascade (Figure 6b) strongly suggests that ERK has a crucial role in the regulation of glioblastoma apoptogenesis. In addition, ERK activity is also involved in the activation of a death receptor-mediated extrinsic pathway,36 again highlighting its complex regulatory role in glioblastoma carcinogenesis. In spite of the remarkable CM fermentation-triggered p38 MAPK phosphorylation noted in both glioblastoma cell lines (Figure 5), this signaling activity has been demonstrated to be unrelated to the functioning of the apoptogenic machinery, because the blockade of p38 MAPK activity cannot affect the apoptogenesis (Figure 6). The exact role of p38 MAPK signaling cascade in the induced biological effect requires further elucidation.

Contrary to a previous study in which aqueous extract of CM induced breast cancer cell apoptosis through Akt inactivation,25 the kinase inhibitor pretreatment in this study clearly pointed out that the CM-induced transient Akt activation, at least in part, participated in the inducible apoptogenesis of GBM8401 cells (Figure 6a). In fact, cordycepin was also found...
to activate AMP-activated protein kinase (AMPK), which is a key energy sensor having a critical and negative role in the regulation of fatty acid synthesis. Inhibition of fatty acid synthase has recently been demonstrated to induce caspase-8-mediated tumor cell apoptosis, but not caspase-9-mediated tumor cell apoptosis. This again coincides with and supports the observation that only caspase-8 was activated in apoptotic glioblastoma cells (Figure 3). However, inconsistent with the canonical concept that the activation of Akt pathway exhibits an antiapoptotic effect, our data indicated that the transiently induced Akt phosphorylation contributed to the CM-driven GBM8401 cell apoptosis due to the fact that pretreatment with Akt kinase inhibitor wortmannin unequivocally rescued cell death in GBM8401 cells (Figure 6a), but potentiated cytotoxicity in U-87MG cells (Figure 6b). This differential phenomenon raises the possibility that the upregulated Akt activity might be responsible for AMPK activation and subsequent caspase-mediated apoptogenesis and autophagic induction, but not for antiapoptotic signaling.

In the context of the role of PI3K/Akt/mTOR autophagy pathway in oncogenic regulation, Akt as the major player downstream class I PI3K can activate mTOR and lead to inhibition of autophagy. Conversely, class III PI3K can induce autophagy and the class III PI3K inhibitors, such as LY294002 and wortmannin, can repress the autophagy process. In fact, Beclin-1 and class III PI3K, two components of the autophagy-inducing complex, have been demonstrated as direct substrates of caspase-3 and caspase-8 in response to different inducers of both intrinsic and extrinsic apoptotic pathways. Moreover, the antiapoptotic Bcl-2 protein is known to form complexes with Beclin-1 and inhibits autophagy; thus, it has been proposed as a key cross-talking mediator between apoptosis and autophagy. In this regard, the CM-triggered Bcl-2 downregulation may also contribute to induction of autophagic cell death. It is noteworthy that cordycepin is more recently demonstrated to induce both apoptosis and autophagy in breast cancer cells. Consistently, the findings of this study also support that the autophagic induction is most likely involved in the CM-driven glioblastoma cell death. The molecular mechanisms by which CM mycelial fermentation exhibits proapoptogenesis and autophagic induction in glioblastoma cells are schematically proposed in Figure 7.

In conclusion, here we presented that CM and its mycelial fermentation can halt the cell cycle, stimulate chromosomal DNA breakdown, and ultimately result in both apoptotic and autophagic cell death of cultured glioblastoma cells. The extracellular components obtained by submerged mycelial culture of CM potently inhibited cell proliferation of human glioblastoma GBM8401 and U-87MG cells by inducing growth arrest at the G0/G1 and G2/M phases, respectively. This is the first report describing the antiapoptgblastoma cell activity derived from the submerged culture of CM. The CM fermentation could interrupt cell cycle progression of cultured glioblastoma cells through the p53–p21 signaling axis and induce chromosomal DNA disintegration and subsequent apoptosis through Bcl-2 and Bax disequilibration, caspase activation, as well as autophagic induction. Signaling delineation and kinase pretreatment study mechanistically demonstrated the involvement of PI3K/Akt and MEK1 pathways in CM-driven glioblastoma cytotoxicity. Accordingly, our findings suggest that the mycelia fermentation of CM may have clinical therapeutic potential against human glioblastoma and will be clinically useful in the future.

Materials and Methods

Micro-organ and flask culture conditions. C. militaris (CM, Linnaeus) Link BCRC 32219 (= ATCC 26848) used in this study was obtained from the Biosource Collection and Research Center (BCRC, Hsinchu, Taiwan). The culture medium composition for the fermentation was comprised of 10 g/l of dextrose, 3 g/l of malt extract, 5 g/l of peptone, and 3 g/l of yeast extract. The pH was initially adjusted to 6, followed by autoclaving. The flask culture experiments were accomplished in 250 ml flasks containing 3% (v/v) inoculum of CM and 100 ml of culture medium. The culture was cultivated at 20 °C in a rotary shaker incubator at 150 r.p.m., and samples were collected at various intervals for analyzing the biomass dry weight, the production of exopolysaccharide, and intracellular polysaccharide. The mycelia biomass and culture supernatants were collected and separated by centrifugation at 10 000 × g for 30 min. The centrifuged pellets were then thoroughly rinsed with a large amount of distilled water, followed by lyophilization and dry weight determination. The lyophilized powder was then dissolved in serum-free RPMI or DMEM media and filtered through a 0.22 μm filter and stored at 4 °C. All experiments were carried out at least in triplicate and the results were averaged.

Cell culture. Human MCF-7 breast cancer cells (BCRC 60436), mouse 3T3 fibroblasts (BCRC 60071), human GBM8401 (BCRC 60163), and U-87MG (BCRC 60360) glioblastoma cells were purchased from BCRC. 3T3 fibroblasts, MCF-7, and U-87MG cells were cultured in DMEM, unless GBM8401 cells were grown in RPMI 1640. All media were supplemented with 10% FBS and 1% antibiotics, including penicillin and streptomycin, and cells were cultured in a humidified 5% CO2 environment at 37 °C.

Cell viability analysis. Viability of control and treated cells was evaluated using MTT assay in triplicate. Cells (1 × 104 per well) were seeded in 96-well microtiter plates containing 100 μl culture medium per well at 24 h before treatment. After 24 h of treatment with the test compounds (lyophilized products), cells were incubated at 37 °C in 200 μl MTT solution (1 mg/ml) for 4 h. After removal of the medium and MTT, 100 μl of DMSO was added to each well and the absorbance of untreated cells was considered as 100%.
Flow cytometry. For cell cycle and hypodiploid DNA analyses, the treated cells were harvested with trypsin, washed with PBS, and fixed in 75% ethanol for at least 2 h at 4 °C. Before analysis, the cells were washed once again with PBS, suspended in a cold 0.1% (w/v) sodium citrate solution containing 100 μg/ml RNase A, 50 μg/ml PI, and 0.1% (v/v) NP-40, and further incubated on ice for 30 min in the dark. Flow cytometric analyses were carried out using a flow cytometer (FACSCalibur; Becton Dickinson, San Jose, CA, USA), and CellQuest software (Becton-Dickinson) was used to determine the relative DNA content based on the presence of PI-positive red fluorescence. Sub-G1 population was discriminated by plotting PI-positive events in a logistic scale of histogram to estimate the apoptotic cell population. For the analysis of cell cycle distribution, the sub-G1 population was gated out and non-apoptotic cells were shown on a histogram with a linear scale for DNA content. To detect the Annexin V-positive apoptotic cells, the treated cells were trypsinized and fixed in ice-cold methanol. The cells were then subjected to Annexin V-FITC and PI staining according to the manufacturer’s instructions (Calbiochem Merck, Darmstadt, Germany). Cell cycle distribution in histogram and Annexin V quadrant analyses were analyzed by using the WinMDI software (designed by Dr. Joseph Trotter, the Scripps Research Institute, USA, version 2.8).

DAPI nuclear staining for chromosomal condensation. Cells were seeded in a 6-cm dish with 2 ml serum medium, which contained 6 × 105 cells/cm2. After cells reached 70–80% confluence, cells were treated with extracts for 24 h at various doses (0.5, 1, 1.5, 2, and 2.5 mg/ml). Cells were fixed with ethanol, washed with PBS, and stained with 2.5 μg/ml DAPI (Sigma-Aldrich China, Shanghai, PR China) solution for 10 min at room temperature. The cell was washed two more times with PBS and observed under a fluorescent microscopy (Nikon Corporation, Tokyo, Japan). Apoptotic nuclear change is characterized by the varied nuclear size and appearance of chromosomal condensation.

Caspace activity assay. The lysates from the cells with 6 h of treatment were subjected to assessment of caspase-3, caspase-8, and caspase-9 activities by an ApoAlert caspase assay kit (Clontech, Mountain View, CA, USA). The caspase activity was luminometrically measured by Luminoskan Ascent microplate reader (Thermo Scientific, Vienna, VA, USA) and readings were normalized by total protein.

Statistical analysis. All results were expressed as mean ± standard deviation (S.D.). Each value is the mean of at least three separate experiments. The differences between negative control and treatment groups were analyzed by Student’s t-test. P-values < 0.05 were declared as significant.

Conflict of Interest
The authors declare no conflict of interest.

Acknowledgements. This work was financially supported by a grant from I-Shou University, E-Da Hospital, and the National Science Council of Taiwan.
38. Thomson DM, Winder WW. AMP-activated protein kinase control of fat metabolism in skeletal muscle. Acta Physiol (Oxf) 2009; 196: 147–154.

39. Knowles LM, Yang C, Osterman A, Smith JW. Inhibition of fatty-acid synthase induces caspase-8-mediated tumor cell apoptosis by up-regulating DDIT4. J Biol Chem 2008; 283: 31378–31384.

40. Chen S, Rehman SK, Zhang W, Wen A, Yao L, Zhang J et al. Autophagy is a therapeutic target in anticancer drug resistance. Biochim Biophys Acta 2010; 1806: 220–229.

41. Cho DH, Jo YK, Hwang JJ, Lee YM, Roh SA, Kim JC et al. Caspase-mediated cleavage of ATG6/Beclin-1 links apoptosis to autophagy in HeLa cells. Cancer Lett 2009; 274: 95–100.

42. Djavaheri-Mergny M, Mauri MC, Kroemer G. Cross talk between apoptosis and autophagy by caspase-mediated cleavage of Beclin 1. Oncogene 2010; 29: 1717–1719.

43. Choi S, Lim MH, Kim KM, Jeon BH, Song WO, Kim TW et al. Cordycepin-induced apoptosis and autophagy in breast cancer cells are independent of the estrogen receptor. Toxicol Appl Pharmacol 2011; 257: 165–173.

Supplementary Information accompanies the paper on Cell Death and Disease website (http://www.nature.com/cddis)